Background: Recent studies questioning the benefit of prostatespecific antigen (PSA) screening have increased the need for evaluating factors contributing to variance in levels and their clinical relevance. An inverse relationship between body mass index (BMI) and PSA has been illustrated, however the clinical implications have not been specified. We performed a retrospective review of patients screened through our free screening clinic to delineate any relationship between PSA and BMI in an attempt to understand its possible clinical significance.
P rostate cancer is the most common solid tumor in American men and the second leading cause of cancerrelated mortality. 1 Early detection has important implications for patient care and healthcare costs. Prostate-specific antigen (PSA) was introduced in the 1980s as a marker for identifying prostate cancer, and in 1992 the American Cancer Society recommended the use of PSA in routine screening for prostate cancer. Use of PSA for screening resulted in a significant increase in prostate cancer detection with an average annual increase in incidence of 16.4% between 1988 and 1992. 2 Importantly, this increase in incidence has coincided with an increase in the proportion of newly diagnosed patients who have clinically localized disease to a current level of 80%.
Although the detection of prostate cancer has become more common since the introduction of PSA, overall mortality remains high with an estimated 27,360 deaths in 2009, and relative survival of patients diagnosed with prostate cancer has changed little. 2 Recent studies have questioned whether screening 'using PSA has resulted in decreased mortality from prostate cancer. [3] [4] [5] [6] The European Randomized Study of Screening for Prostate Cancer noted a 20% reduction in rate of death related to prostate cancer, but cautioned against the risk of overdiagnosis. This study also indicated that 1410 patients would have to be screened and 48 treated to prevent 1 prostate cancer-related death. 4 In the United States, the Prostate, Lung, Colon and Ovarian Cancer Screening Trial showed no difference in the rate of death between patients undergoing annual screening and those patients in usual care. 3 One possible reason that screening for prostate cancer using PSA has not achieved reduced mortality is that PSA can be confounded by weight. Several studies have demonstrated an inverse relationship between PSA and body mass index (BMI). [7] [8] [9] [10] [11] [12] [13] In 1 study, PSA decreased by 5.9% for every 5.2 kg/m 2 increase in BMI. 8 As about one-third of American men are obese, if the relationship between BMI and PSA is indeed clinically significant, this could have large implications on the interpretation of PSA levels. 14 This could explain why elevated BMI has been associated with an increased mortality and higher Gleason scores at diagnosis, although it is noted the association is inconsistent. [15] [16] [17] The goal of this study was to evaluate the relationship between PSA level and BMI. We hypothesized that men with an increased BMI would have decreased PSA levels.
MATERIALS AND METHODS
This was an observational cohort study using data collected by a community outreach program designed to increase awareness of prostate cancer and accessibility to prostate cancer screening in traditionally underserved populations. All procedures were approved by the local Institutional Review Board with written and informed consent obtained from all patients.
Subjects Z40 years of age with a current PSA level, height and weight recorded were eligible for inclusion in this study. Subjects with a previous diagnosis of prostate cancer, previous resection of the prostate for benign conditions, endocrinologic conditions that could alter baseline PSA, and previous or ongoing hormone modulating medications (eg, saw palmetto, proscar, avodart, and androderm) were excluded. The Siemens (Bayer) chemiluminescent method was used for PSA level determination. PSA levels Z4.0 ng/mL were considered elevated. BMI was calculated as the weight in kilograms divided by the square of the height in meters. The mean and standard deviation have been used as measures of central tendency and spread. Frequencies and percentages have been used to describe categorical variables. Subjects could have had more than 1 visit during the study period, so a mixed-effects linear model was used to estimate the effect of BMI on PSA. The model was adjusted for race and age. Analyses were conducted using SPSS v 17.0 (SPSS Inc, Chicago, IL).
RESULTS
There were 1514 visits between June 2003 and August 2009. There were 206 visits excluded for patients with a history of prostate cancer, prostate surgery, previous use of hormone modulating medications, or age <40 years. Height or weight was not assessed at 319 visits, PSA values were either missing or out of range for 4 visits and race was unknown for 2 visits. These visits were also excluded, resulting in 983 visits by 767 unique patients being included in the analysis. Characteristics of the included and excluded subjects are detailed in Table 1 .
Of the 767 patients with at least 1 visit meeting inclusion criteria, the mean age at first PSA was 54 (SD 9) years, and 72% were African American. Mean BMI was 28.7 kg/m 2 (SD 5.4); 78% were overweight or obese (BMI Z25). Mean PSA was 1.28 (SD 1.77) ng/mL; 44 patients had at least 1 PSA level over 4.0 ng/mL. There was a small, but statistically significant trend toward decreasing PSA for an increasing BMI (Fig. 1) ; for every unit increase in BMI, PSA decreased by 0.026 ng/mL. In addition, for every unit increase in age, PSA increased by 0.034 ng/mL ( Table 2) . These values illustrated in the table serve to provide estimations of the deduction or contribution on PSA value that obesity and age provide, respectively.
DISCUSSION
Consistent with previous research, this study suggests there is a negative association between BMI and PSA levels. The degree of association is similar to that identified in other studies, and also to studies showing associations between PSA and lean and fat mass ratios and waist circumference. [7] [8] [9] [10] Clinical utility of this finding has yet to be demonstrated and our data show that it is likely to be of limited relevance for application to routine screening; assuming a linear relationship, the BMI would have to change by 40 kg/m 2 to result in a change in PSA levels of 1 ng/mL. Although the individual associations are small, in combination they might attain clinical relevance and might be considered when evaluating the need for further testing (eg, biopsy) for patients with PSA values close to the common normal limit of 4.0 ng/mL. However, we do not believe the associations observed in our study warrant a reassessment of this normal value.
There are inherent limitations recognized in our study. As this is a research population obtained through a community outreach program, we have a specific subset of patients that may not be representative of the population at large. This would clearly preclude any outcomes-based analysis. However, we feel that this subset still serves to assess an association between the clinical parameter of BMI and the currently accepted screening standard of care, PSA. There are additional risk factors for prostate cancer, which can be prospectively or retrospectively analyzed in a screening population including: free PSA, PSA velocity, fat distribution, lean and fat mass ratios, palpable prostate abnormalities, and serum testosterone levels. Given the natural limitations of our study population as a screening population with limited funding, our analysis captures the stated aim of an association between BMI and PSA. This association has been attributed to different factors, which include alteration in androgen levels owing to obesity as well as hemodilution. 10, 11 The relative risk of prostate cancer owing to these biochemical changes is not clearly defined and PSA serves as an intermediary to these potential effects.
As debate continues as to the utility of using PSA levels to screen for prostate cancer, [3] [4] [5] [6] our study suggests that the association between BMI and PSA level is of insufficient magnitude to broadly impact the sensitivity or specificity of PSA levels to prostate cancer. The overall benefit of prostate screening under the currently recommended parameters remains to be determined.
CONCLUSIONS
Our study found a quantitative association between PSA and BMI. The magnitude of effect does not appear to justify changing the accepted limit of normal for obese persons, although the decision to conduct further testing might be informed when considering obesity in combination with other factors known to impact PSA levels. 
